Black Diamond Therapeutics Inc.'s development of cancer therapies using lab-based systems to find and refine drug candidates infringes six patents, a Michigan-based company’s federal lawsuit said.
HMI Medical Innovations LLC alleged Black Diamond’s use of methods for identifying and optimizing compounds targeting drug-resistant cancer proteins infringes US Patent Nos. 8,431,110, 9,645,137, 10,018,619, 9,795,610, 9,579,326, and 8,367,038, in a complaint filed Tuesday in the US District Court for the District of Delaware.
HMI, which develops and licenses patented medical innovations, said its technology improves how researchers identify and optimize compounds that act on mutated proteins ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.